Skip to main navigation
Skip to content
Skip to primary sidebar
Skip to footer
240.243.1201
info@glycomimetics.com
Careers
Contact Us
Investor Relations
About Us
Board of Directors
Management Team
Core Values
Patients
Clinical Trials
Expanded Access
Pipeline
Programs
Uproleselan/GMI-1687
Rivipansel (GMI-1070)
GMI-1359
Galectin Inhibitors
Therapeutic Focus
Acute Myeloid Leukemia (AML)
Sickle Cell Disease
Technology & Publications
Intellectual Property
Scientific Publications
Platform & Research
Collaborations
Investors
Press Releases
Corporate Presentation
Events & Presentations
Corporate Govenance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Ownership Profile
Contact Us
PRESS RELEASES
Investor Relations
About Us
Board of Directors
Management Team
Core Values
Patients
Clinical Trials
Expanded Access
Pipeline
Programs
Uproleselan/GMI-1687
Rivipansel (GMI-1070)
GMI-1359
Galectin Inhibitors
Therapeutic Focus
Acute Myeloid Leukemia (AML)
Sickle Cell Disease
Technology & Publications
Intellectual Property
Scientific Publications
Platform & Research
Collaborations
Investors
Press Releases
Corporate Presentation
Events & Presentations
Corporate Govenance
Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Annual Reports and Proxies
Quarterly Results
Key Ratios
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Ownership Profile
Contact Us
PRESS RELEASES
More news releases are coming soon.
Shareholder Tools
Print
Print
Printed Materials
Printed Materials
Email Alerts
Email Alerts
Downloads
Downloads
RSS
RSS
Search
Search
